was adjusted during the MILES trial to maintain a serum trough between 5 and 15 ng/mL.
INTRODUCTION
Lymphangioleiomyomatosis (LAM) is a multisystem disorder that primarily affects women and is characterized by proliferation of abnormal smooth muscle-like cells with associated cystic lung destruction and abdominal tumors, such as renal angiomyolipoma and lymphangioleiomyomas. [1, 2] The double-blind, randomized Multicenter International LAM Efficacy of Sirolimus (MILES) trial demonstrated that sirolimus stabilized lung function and improved quality of life and functional performance. [2] Sirolimus is now recommended for LAM patients with abnormal forced expiratory volume in 1 s (FEV1 <70%) predicted or declining lung function. [3] Sirolimus therapy was also reported to be associated with improvement or reduction in size of chylous effusions and lymphangioleiomyomas. [4] Optimal dose and duration are unsettled. Nonetheless, the sirolimus dose nonmassive hemoptysis with characteristic diffuse thin-walled cysts on chest computed tomography (CT) and elevated vascular endothelial growth factor-D (VEGF-D) level (4458 pg/mL). Abdominal and pelvic CT showed a large lobulated cystic and solid mass in the retroperitoneal region compatible with lymphangioleiomyoma [ Figure 1 ]. The large multicystic lesion involving a large portion of retroperitoneum abutted the kidneys and encased both the descending aorta and inferior vena cava. No intra-abdominal adenopathy, ascites, or intrarenal lesion was identified. Pulmonary function test showed preserved FEV1/forced vital capacity (FVC) ratio with FEV1 4.11 L (112%) and FVC 5.04 (116%) but a reduced diffusing capacity of the lungs for carbon monoxide (DLCO) (59% predicted). Sirolimus was offered as a treatment option due to exertional dyspnea and hypoxemia in association with the reduced DLCO and the large, intra-abdominal disease burden. The patient tolerated sirolimus at 1 mg daily and remained on the same dose with the mean serum trough level at 2.98 ± 1.39 ng/mL. Her respiratory symptoms improved with stabilized FEV1 4.18 L (116%) and DLCO 56% after 14 months of sirolimus treatment. Repeat CT of chest, abdomen, and pelvis revealed stable pulmonary cystic lesions and nearly complete resolution of the retroperitoneal mass [ Figure 1 ].
DISCUSSION
Lymphangioleiomyomas occur most often in the retroperitoneal region and have been observed more frequently in patients with sporadic LAM (29%) than in tuberous sclerosis complex patients with LAM (9%). [6] Extrapulmonary LAM cells form fascicles and papillary patterns that are commonly found in lymph nodes along lymphatic vessels. [7] Lymphangioleiomyoma-LAM cells have infiltrated the fatty capsule surrounding the mass. [8] In addition, chyle-filled cystic lesions resulted from the obstruction of lymphatic vasculature by proliferation of smooth muscle cells. [7, 8] Large lesions such as those seen in this case can encase and compress adjacent organs. Our patient also had a markedly high VEGF-D level, which has been shown to reflect lymphatic involvement and negatively correlate with pulmonary function in patients with LAM. [9] Historically, lymphangioleiomyomas were primarily managed with surgical resection but may recur after surgical removal. More recently, medical treatment with sirolimus has surfaced as beneficial due to its favorable effect on lymphangioleiomyoma size. [4, [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] Nonetheless, the optimal sirolimus dose and serum level remain undetermined. A review of published case reports and series of LAM patients with abdominal lymphangioleiomyomas who received sirolimus therapy is summarized in Table 1 . Most had dramatic reduction of mass with sirolimus trough level >5 ng/ mL. In contrast, the effect of sirolimus also remained significant in several cases with serum trough level <5 ng/mL as was the case in our patient. [11, 12] Loss of beneficial effect occurred in the MILES trial; therefore, long-term treatment is generally required.
Low-dose sirolimus has the potential to reduce adverse effects and may enhance the safety of long-term therapy. Multicenter Interventional LAM Early Disease (MILED) trial to determine the efficacy of low-dose sirolimus (fixed dose at 1 mg daily) for preventing progression of disease in patients with well-preserved lung function is underway (NCT03150914). Nonetheless, abdominal tumor size is not a primary outcome in MILED trail. Our report reinforces the role of medical therapy for lymphangioleiomyomas that can avoid unnecessary surgery. In addition, favorable responses of extrapulmonary LAM to low-dose sirolimus therapy that is well tolerated are important to report to contribute to the available literature on treatment of this rare disease.
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